CLDF Title
Home | Contact Us | Bookmark
HBV HE HCC HCV
About CLDF Centers of Educational Expertise  
Live CME Meetings Telewebs Webcasts Slide Library Abstract Library Conference Highlights
 
Back  
 
Reuters Health Information (2010-02-12): Hydroxycut linked to other cases of liver damage

Epidemiology

Hydroxycut linked to other cases of liver damage

Last Updated: 2010-02-12 19:01:54 -0400 (Reuters Health)

NEW YORK (Reuters Health) - A new study strengthens evidence that the once widely advertised weight-loss supplement Hydroxycut caused serious liver damage in some users.

Last May, 14 Hydroxycut products were recalled by the manufacturer, Canada-based Iovate Health Sciences, after the U.S. Food and Drug Administration issued a warning to all consumers to stop using the supplements.

The warning was based on 23 reports to the agency describing liver damage in Hydroxycut users -- ranging from inflammation to necrosis severe enough to require a liver transplant. The supplement was also linked to one death.

Iovate said in May that it was recalling Hydroxycut because it "became aware that the U.S. Food and Drug Administration's assessment of 23 reports about consumers having experienced liver-related problems, as well as a small number of published case reports, was different from Iovate's analysis."

The company noted that "the number of adverse event reports described by the FDA is small relative to the many millions of people who have used Hydroxycut products over the 7 years."

In the new study, reported online in the American Journal of Gastroenterology, researchers analyzed 17 cases of liver damage among Hydroxycut users that had not yet appeared in the medical literature. Nine of the cases had been reported to the FDA, while eight were seen by the authors of the study.

Looking at factors like patients' risk factors for liver disease and the timing of their Hydroxycut use, the researchers found that in eight cases, there was a greater than 95% likelihood that the weight-loss aid was to blame.

In five cases, the researchers concluded that Hydroxycut was "highly likely" to be the cause (a 75% to 95% chance), while it was probably to blame in two cases (a 50% to 74% chance). The last two cases were considered to be possibly linked to Hydroxycut use.

This type of study cannot definitively prove cause-and-effect -- something that is often "challenging" to do in cases where a drug is suspected of causing a toxic effect, noted study co-author Dr. Tse-Ling Fong, an associate professor of medicine at the University of Southern California, Los Angeles.

This is particularly true of dietary supplements, Dr. Fong told Reuters Health, because they do not have to be tested in clinical trials and little may be known about their side effects.

In their analysis, Dr. Fong and three colleagues each independently assessed records from the 17 cases, including the eight patients who were treated by the researchers between 2002 and 2009, and nine patients whose cases were reported to the FDA.

"Most people who take these weight-loss supplements are otherwise healthy," Dr. Fong noted, "and they are usually young." The average age of patients in this study was about 30.

The findings, according to Dr. Fong, strengthen the evidence that Hydroxycut itself has caused liver damage in some users.

They also show that some of that damage is severe, he noted. Of the 17 patients, three required liver transplantation and one died (the case previously reported to the FDA). The rest of the patients recovered from their symptoms, which included nausea, vomiting, abdominal pain and fatigue.

The recalled Hydroxycut products contained a mix of herbs and other ingredients, like caffeine, and investigators have not yet determined which substances might be behind the liver damage.

Dr. Fong noted that shortly after the May recall, Hydroxycut's manufacturer came out with a "reformulated" weight-loss product called Hydroxycut Advanced -- which, the company says, now contains blueberry extracts, vitamin C and other antioxidants, plus caffeine as the "key" ingredient.

Am J Gastroenterol 2010.

 
 
 
 
                 
 
HBV
Webcasts
Slide Library
Abstract Library
 
HE
Live CME Meetings
Webcasts
Slide Library
Abstract Library
 
HCC
Slide Library
Abstract Library
 
 
HCV
Live CME Meetings
Webcasts
Slide Library
Abstract Library
 
CLDF Follow Us
   
 
About CLDF
Mission Statement
Board of Trustees
Board of Advisors
CLDF Supporters
 
Other Resources
Liver News Library
Journal Abstracts
Hep C Link to Care
 
Centers of
Educational Expertise
Regional Map
     
   
  The Chronic Liver Disease Foundation is a non-profit organization with content developed specifically for healthcare professionals.
© Copyright 2012-2014 Chronic Liver Disease Foundation. All rights reserved. This site is maintained as an educational resource for US healthcare providers only.
Use of this Web site is governed by the Chronic Liver Disease Foundation terms of use and privacy statement.